info on alcohol test strip info on amphetamines info on barbiturates info on buprenorphine info on benzodiazepines info on cocaine info on cotinine info on eddp info on fentanyl info on k2-spice info on ketamine info on mdma-ecstasy info on methamphetamines info on methadone info on opiates info on oxycodone info on phencyclidine info on propoxyphene info on tricyclic anti-depressants info on thc-marijuana info on tramadol


Buprenorphine is a semisynthetic opioid analgesic derived from thebain, a component of opium. It has a longer duration of action than morphine when indicated for the treatment of moderate to severe pain, peri-operative analgesia, and opioid dependence. Low dose buprenorphine produces sufficient agonist effect to enable opioid-addicted individuals to discontinue the misuse of opioids without experiencing withdrawal symptoms. Buprenorphine carries a lower risk of abuse, addiction, and side effects compared to full opioid agonists because of the “ceiling effect,” whereby increased doses of the drug do not produce increased effects after a certain point, or ceiling. However, it has also been shown that buprenorphine has abuse potential and may itself cause dependency. Subutex®, and a buprenorphine/Naloxone combination product, Suboxone®, are the only two forms of buprenorphine that have been approved by FDA in 2002 for use in opioid addiction treatment. Buprenorphine was rescheduled from Schedule V to Schedule III drug just before FDA approval of Suboxone and Subutex.

DrugCheck® drug of abuse tests yield a positive result when the concentration of buprenorphine in urine exceeds 5 ng/mL* or 10 ng/mL, and 5 ng/mL* in saliva.

* Forensic use only